AC Immune (NASDAQ:ACIU) Upgraded to Strong-Buy at Zacks Research

Zacks Research upgraded shares of AC Immune (NASDAQ:ACIU) from a hold rating to a strong-buy rating in a research note published on Tuesday,Zacks reports.

ACIU has been the topic of several other research reports. BTIG Research reaffirmed a “buy” rating and set a $8.00 price target on shares of AC Immune in a research report on Wednesday, September 23rd. HC Wainwright reiterated a “buy” rating on shares of AC Immune in a research report on Thursday, September 24th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of AC Immune in a research note on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $7.50.

AC Immune Price Performance

AC Immune stock opened at $2.62 on Tuesday. The company has a current ratio of 0.93, a quick ratio of 1.02 and a debt-to-equity ratio of 0.11. The company has a 50-day moving average price of $2.59 and a 200 day moving average price of $2.67. AC Immune has a 12-month low of $2.10 and a 12-month high of $4.00. The stock has a market cap of $266.64 million, a P/E ratio of -4.85 and a beta of 1.60.

AC Immune (NASDAQ:ACIU) last posted its earnings results on Thursday, August 6th. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.13. AC Immune had a negative net margin of 245.32% and a negative return on equity of 100.17%. The company had revenue of $18.67 million for the quarter, compared to analyst estimates of $9.59 million. Sell-side analysts anticipate that AC Immune will post -0.6 earnings per share for the current year.

Institutional Trading of AC Immune

Large investors have recently modified their holdings of the stock. Dimensional Fund Advisors LP grew its stake in shares of AC Immune by 82.8% during the first quarter. Dimensional Fund Advisors LP now owns 390,165 shares of the company’s stock worth $1,071,000 after purchasing an additional 176,701 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its holdings in AC Immune by 8.0% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 405,658 shares of the company’s stock worth $1,116,000 after buying an additional 30,035 shares during the last quarter. Finally, AXQ Capital LP acquired a new position in AC Immune in the second quarter valued at approximately $25,000. Hedge funds and other institutional investors own 51.36% of the company’s stock.

AC Immune Company Profile

AC Immune SA (NASDAQ: ACIU) is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland. Founded in 2003, the company develops precision medicines and diagnostic products designed to prevent, diagnose and treat neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease and other conditions associated with misfolded proteins.

AC Immune’s research is based on its SupraAntigen and Morphomer technology platforms, which are intended to identify disease-related proteins and generate therapies or diagnostic tools that target them.